	US 11,865,084 B2
	MERS coronavirus vaccine
Susanne Rauch, Tübingen (DE)
Assigned to CureVac SE, Tübingen (DE)
Filed by CureVac SE, Tübingen (DE)
Filed on Sep. 7, 2021, as Appl. No. 17/467,632.
Application 17/467,632 is a division of application No. 16/471,539, granted, now 11,141,476, issued on Oct. 12, 2021, previously published as PCT/EP2017/084564, filed on Dec. 22, 2017.
Claims priority of application No. PCT/EP2016/082669 (WO), filed on Dec. 23, 2016.
Prior Publication US 2021/0401971 A1, Dec. 30, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/215 (2006.01); C07K 14/165 (2006.01); C12N 15/86 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/215 (2013.01) [C07K 14/165 (2013.01); C12N 15/86 (2013.01); A61K 2039/53 (2013.01); C12N 2770/20011 (2013.01)]

14 Claims

1. A pharmaceutical composition comprising an isolated mRNA comprising at least one coding region, encoding a spike protein (S) of a Middle East respiratory (MERS) coronavirus, said coding region being at least 90% identical to a nucleic acid sequence of SEQ ID NO: 2361, wherein the mRNA is associated with lipid nanoparticles (LNPs).